DNA Vaccines against Hamster Oral Papillomavirus Associated Oral Cancer

针对仓鼠口腔乳头瘤病毒相关口腔癌的 DNA 疫苗

基本信息

  • 批准号:
    15591956
  • 负责人:
  • 金额:
    $ 2.18万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2004
  • 项目状态:
    已结题

项目摘要

In a previous investigation, we developed a highly reproducible carcinogenesis model by combining DMBA application with physical wounding of the hamster lingual mucosa. Using this animal model, we demonstrated the presence of a novel hamster oral papillomavirus (HOPV) by the molecular cloning and sequencing of this viral genome.In this study, we used this HOPV hamster model to test whether vaccination with either the L1, E6 or E7 genes alone and pDNA/mBSA complex could prevent oral carcinoma development.An immunization protocol using intramuscular injection of DNA plasmids encoding the L1, E6 or the E7 gene, pDNA/mBSA or vector only, respectively was initiated to hamsters. The lingual tips of hamsters were painted three times a week with DMBA for 8 weeks. The middle portion of the lingual tip, 2 mm in longitudinal thickness, was then excised under anaesthesia. Thereafter, the tips were painted daily with DMBA until the animals were sacrificed.The all vector-injected hamsters showed lingual carcinoma. Some delay in cancer development in both of genes alone and pDNA/mBSA complex of the L1, E6 and E7-vaccinated hamsters was observed. In particular, L1 pDNA/mBSA complex vaccinated hamsters showed no lesions.Using the electrochemotherapy, anti-cancer effects were enhanced in L1 gene vaccine.These results suggested that immunization with L1, E6 and E7 DNA vaccines delayed carcinoma development of papillomavirus-associated oral cancer and electrochemotherapy is very useful technique for the insert DNA vaccines to the cells of tissues.
在以前的研究中,我们开发了一个高度可重复的致癌模型相结合的DMBA应用与仓鼠舌粘膜的物理创伤。利用该动物模型,我们通过对该病毒基因组的分子克隆和测序证实了一种新的仓鼠口腔乳头瘤病毒(HOPV)的存在。在本研究中,我们使用该HOPV仓鼠模型来测试单独接种L1、E6或E7基因以及pDNA/mBSA复合物是否可以预防口腔癌的发生。E6或E7基因、pDNA/mBSA或仅载体分别起始于仓鼠。用DMBA涂抹仓鼠舌尖,每周3次,共8周。然后在麻醉下切除舌尖的中间部分,纵向厚度为2 mm。此后,每天用DMBA涂抹尖端直到动物被处死。所有载体注射的仓鼠都显示舌癌。在单独的基因和L1、E6和E7接种的仓鼠的pDNA/mBSA复合物中观察到癌症发展的一些延迟。结果表明,L1、E6和E7 DNA疫苗免疫后,可延缓乳头瘤病毒相关性口腔癌的发生发展,而电化学疗法可使L1基因疫苗的抗肿瘤作用增强。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MAEDA Hatsuhiko其他文献

Effects of Low Reactive Level Laser Therapy on the Progress of Bone Healing
低反应水平激光治疗对骨愈合进程的影响
  • DOI:
    10.5984/jjpnsoclaserdent.30.49
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    HONDA Yuma;SUGITA Yoshihiko;YOSHIYAMA Masanori;HATTORI Takehiro;ISOMURA Madoka;KAWAI Ryoko;YOSHIDA Waka;KUBO Katsutoshi;NIWA Yukari;NAKANO Kenjiro;HAYASHI Kensuke;FUJITANI Morioki;SENDA Akira;MAEDA Hatsuhiko
  • 通讯作者:
    MAEDA Hatsuhiko

MAEDA Hatsuhiko的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MAEDA Hatsuhiko', 18)}}的其他基金

Strategic Survey of Trends Toward Oral Pathology Standardization and Oral Pathology Board Certification in Asia for the New Century
新世纪亚洲口腔病理学标准化和口腔病理学委员会认证趋势的战略调查
  • 批准号:
    22406031
  • 财政年份:
    2010
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Basic research of the antigen delivery system that it aimed at the optimization of the DNA vaccine for cancer prevention
抗原传递系统的基础研究,旨在优化用于癌症预防的DNA疫苗
  • 批准号:
    20592166
  • 财政年份:
    2008
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The study of DNA vaccine potency against hamster oral papillomavirus-associated oral cancer
DNA疫苗对抗仓鼠口腔乳头瘤病毒相关口腔癌的效力研究
  • 批准号:
    18592022
  • 财政年份:
    2006
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of a DNA vaccine of the papillomavirus
乳头瘤病毒DNA疫苗的研究
  • 批准号:
    13671928
  • 财政年份:
    2001
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research if interactions between chemical carcinogens, physical irritations and papillomavirus in carcinogenesis
研究化学致癌物、物理刺激和乳头瘤病毒在致癌过程中的相互作用
  • 批准号:
    11671832
  • 财政年份:
    1999
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Targeting DKK1 with a DNA Vaccine to Prevent Development of Multiple Myeloma
用 DNA 疫苗靶向 DKK1 预防多发性骨髓瘤的发展
  • 批准号:
    10874135
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine
临床就绪的 MACH-1 基因枪,用于提供通用流感 DNA 疫苗
  • 批准号:
    10761364
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
  • 项目类别:
A Single-dose DNA vaccine platform to safely induce protective immunity against Zika
单剂量 DNA 疫苗平台可安全诱导针对寨卡病毒的保护性免疫力
  • 批准号:
    10026208
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Small Business Research Initiative
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
  • 批准号:
    10340654
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
  • 批准号:
    10571883
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
整合素激活剂佐剂 DNA 疫苗对抗克氏锥虫感染
  • 批准号:
    10665082
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
整合素激活剂佐剂 DNA 疫苗对抗克氏锥虫感染
  • 批准号:
    10544403
  • 财政年份:
    2022
  • 资助金额:
    $ 2.18万
  • 项目类别:
Development of an intradermal or inhaled DNA vaccine for COVID-19 and beyond
开发针对 COVID-19 及其他疾病的皮内或吸入 DNA 疫苗
  • 批准号:
    2599978
  • 财政年份:
    2021
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Studentship
A novel DNA vaccine that delivers long lasting immunity by stimulating high avidity CD8 T cells and strong neutralising antibodies
一种新型 DNA 疫苗,通过刺激高亲和力 CD8 T 细胞和强中和抗体来提供持久的免疫力
  • 批准号:
    73437
  • 财政年份:
    2020
  • 资助金额:
    $ 2.18万
  • 项目类别:
    Collaborative R&D
Vaccination with self-launching RhCMV/SIV DNA vaccine vectors
使用自启动 RhCMV/SIV DNA 疫苗载体进行疫苗接种
  • 批准号:
    10037603
  • 财政年份:
    2020
  • 资助金额:
    $ 2.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了